Anakinra in the treatment of acute calcium pyrophosphate arthritis

A multicentre, randomised, controlled, double-blind study, evaluating the efficacy and safety of anakinra in chondrocalcinosis (Étude multicentrique randomisée contrôlée en double-aveugle contre placebo, évaluant l?efficacité et la sécurité de l?anakinra dans la crise de chondrocalcinose articulaire)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN46471047

Enrollment

Registered

2011-03-18

Start date

2011-05-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chondrocalcinosis Musculoskeletal Diseases Other chondrocalcinosis

Interventions

3 x daily injection of anakinra 100mg versus 3 x daily oral intake of prednisolone 30mg. The primary end point is at day 7 and the study will run over a total of 28 days.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Informed consent 2. Male or female from 18-99 years of age 3. Diagnosis of acute calcium pyrophosphate arthritis based on symptoms of acute arthritis and presence of crystals of chronic calcium pyrophosphate dihydrate (CPPD) in the synovial liquid at screening or from a prior analysis 4. The start of the acute arthritis should be less than 5 days from inclusion in the study

Exclusion criteria

Exclusion criteria: 1. Corticotherapy orally with dose equivalent of prednisone > 10mg during the 24 h preceding inclusion 2. Corticotherapy intramuscular (im) or intravenous (iv) during the 72h preceding inclusion, no matter the dose 3. Corticotherapy intra-articularly during 7 days preceding inclusion 4. Chronic oral corticotherapy of > 10mg daily 5. Uncontrolled respiratory or cardiac failure 6. Other causes of acute arthritis 7. Active gastric or duodenal ulceration 8. Untreated and active malignancy 9. Known intolerance or allergy to the study medications 10. Active and untreated infection assessed by investigator as a contraindication to study medications 11. Other medical problems that are judged prejudicial to the inclusion of the patient in the study by the investigator 12. Pregancy or active breast feeding

Design outcomes

Primary

Measure	Time frame
Visual Analogue Scale (VAS) pain score of arthritis in the target joint at 72h	—

Secondary

Measure	Time frame
1. Effect of therapy on pain and symptoms of arthritis up to day 28 using a VAS and Likert scales for pain and patient and physician assessment of signs and symptoms of inflammation 2. Tolerance and side effects of the treatments will be assessed by the investigators	—

Countries

Switzerland

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026